 |
|
|
| |
Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results From a Phase 3 Clinical Trial
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 Boston
Lai Wei,1 Qing Xie,2 Yan Huang,3 Shanming Wu,4 Min Xu,5 Hong Tang,6 Jun Cheng,7 Yanhang Gao,8 Zhuangbo Mou,9 Xiaoguang Dou,10 Yuemin Nan,11 Qin Ning,12 Yimin Mao,13 Luisa M. Stamm,14 Sophia Lu,14 Hadas Dvory-Sobol,14 Hongmei Mo,14 Diana M. Brainard,14 Yongfeng Yang,15 Guiqiang Wang,16 Peng Hu,17 Lunli Zhang,18 Zhiliang Gao,19 Feng Lin,20 Jia Shang,21 Guozhong Gong,22 Jun Li,23 Minghua Su,24 Zhong Ping Duan,24 Jinlin Hou,25 Jidong Jia26
1Peking University People's Hospital, Beijing, China; 2Ruijin Hospital, Shanghai, China; 3Xiangya Hospital, Central South University, Changsha, China; 4Shanghai Public Health Clinical Center, Shanghai; 5Guangzhou Eighth People's Hospital, Guangzhou, China; 6West China Medical Center of Sichuan University, Chengdu, China; 7Beijing Ditan Hospital, Capital Medical University, Beijing; 8The First Hospital of Jilin University, Changchun, China; 9Jinan Infectious Disease Hospital, Jinan, China; 10Shengjing Hospital of China Medical University, Shenyang, China; 11The Third Hospital of Hebei Medical University, Shijiazhuang, China; 12Tongji Hospital, Shanghai; 13Renji Hospital, Shanghai; 14Gilead Sciences, Inc., Foster City, CA; 15The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China; 16Peking University First Hospital, Beijing; 17The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China; 18The First Affiliated Hospital of Nanchang University, Nanchang, China; 19The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou; 20Hainan General Hospital, Haikou, China; 21Henan People's Hospital, Zhengzhou, China; 22The Second Xiangya Hospital of Central South University, Changsha; 23The First Affiliated Hospital of Nanjing Medical University, Nanjing; 24Beijing You'an Hospital, Beijing; 25Nanfang Hospital, Guangzhou; 26Beijing Friendship Hospital, Beijing
References: 1. Polaris Observatory HCV Collaborators. Lancet Gastroenterol Hepatol 2017;2:161-76; 2. Chen Y, et al. Emerg Microbes Infect 2017;6:e95; 3. Jacobson IM, et al. N Engl J Med 2013;368:1867-77; 4. Lawitz E, et al. N Engl J Med 2013;368:1878-87; 5. Cheng G, et al. EASL 2013, poster 1191; 6. German P, et al. EASL 2013, poster 1195; 7. Lawitz E, et al. J Vir Hep 2015;22:1011-9; 8. Buggisch P, et al. EASL 2017, poster SAT-254; 9. Curry MP, et al. N Engl J Med 2015;373:2618-28; 10. Curry MP, et al. EASL 2017, abstr PS-102; 11. Feld J, et al. N Engl J Med 2015;373:2599-607; 12. Foster G, et al. N Engl J Med 2015;373:2608-17; 13. Landis C, et al. AASLD 2017, abstr 1096; 14. Rao H, et al. J Gastroenterol Hepatol 2014;29:545-53. Acknowledgments: We extend our thanks to the patients and their families. This study was funded by Gilead Sciences, Inc.
Disclosures: L. Wei: Gilead, AbbVie, BMS, MSD, Roche; Q. Xie, Y. Huang, S. Wu, M. Xu, H. Tang, J. Cheng, Y. Gao, Z. Mou, X. Dou, Y. Nan, Q. Ning, Y. Mao, Y. Yang, G. Wang, P. Hu, L. Zhang, Z. Gao, F. Lin, J. Shang, G. Gong, J. Li, M. Su, Z.P. Duan, J. Hou, and J. Jia: nothing to disclose; L.M. Stamm, S. Lu, H. Dvory-Sobol, H. Mo, and D.M. Brainard: Gilead.
|
| |
|
|
|
|
|
